Refine
Year of publication
Document Type
- Article (29949)
- Part of Periodical (11831)
- Book (8221)
- Doctoral Thesis (5587)
- Part of a Book (3622)
- Working Paper (3370)
- Review (2860)
- Contribution to a Periodical (2278)
- Preprint (1805)
- Report (1545)
Language
- German (41978)
- English (28348)
- French (1067)
- Portuguese (722)
- Multiple languages (306)
- Croatian (302)
- Spanish (301)
- Italian (194)
- mis (174)
- Turkish (148)
Is part of the Bibliography
- no (73865) (remove)
Keywords
- Deutsch (1037)
- Literatur (798)
- taxonomy (737)
- Deutschland (541)
- Rezension (491)
- new species (438)
- Frankfurt <Main> / Universität (341)
- Rezeption (320)
- Geschichte (291)
- Linguistik (268)
Institute
- Medizin (7363)
- Präsidium (5082)
- Physik (4113)
- Extern (2661)
- Wirtschaftswissenschaften (2657)
- Gesellschaftswissenschaften (2366)
- Biowissenschaften (2110)
- Biochemie und Chemie (1949)
- Center for Financial Studies (CFS) (1609)
- Informatik (1576)
Background: 15-20% of all patients initially diagnosed with colorectal cancer develop metastatic disease and surgical resection remains the only potentially curative treatment available. Current 5-year survival following R0-resection of liver metastases is 28-39%, but recurrence eventually occurs in up to 70%. To date, adjuvant chemotherapy has not improved clinical outcomes significantly. The primary objective of the ongoing LICC trial (L-BLP25 In Colorectal Cancer) is to determine whether L-BLP25, an active cancer immunotherapy, extends recurrence-free survival (RFS) time over placebo in colorectal cancer patients following R0/R1 resection of hepatic metastases. L-BLP25 targets MUC1 glycoprotein, which is highly expressed in hepatic metastases from colorectal cancer. In a phase IIB trial, L-BLP25 has shown acceptable tolerability and a trend towards longer survival in patients with stage IIIB locoregional NSCLC.
Methods: This is a multinational, phase II, multicenter, randomized, double-blind, placebo-controlled trial with a sample size of 159 patients from 20 centers in 3 countries. Patients with stage IV colorectal adenocarcinoma limited to liver metastases are included. Following curative-intent complete resection of the primary tumor and of all synchronous/metachronous metastases, eligible patients are randomized 2:1 to receive either L-BLP25 or placebo. Those allocated to L-BLP25 receive a single dose of 300 mg/m2 cyclophosphamide (CP) 3 days before first L-BLP25 dose, then primary treatment with s.c. L-BLP25 930 mug once weekly for 8 weeks, followed by s.c. L-BLP25 930 mug maintenance doses at 6-week (years 1&2) and 12-week (year 3) intervals unless recurrence occurs. In the control arm, CP is replaced by saline solution and L-BLP25 by placebo. Primary endpoint is the comparison of recurrence-free survival (RFS) time between groups. Secondary endpoints are overall survival (OS) time, safety, tolerability, RFS/OS in MUC-1 positive cancers. Exploratory immune response analyses are planned. The primary endpoint will be assessed in Q3 2016. Follow-up will end Q3 2017. Interim analyses are not planned.
Discussion: The design and implementation of such a vaccination study in colorectal cancer is feasible. The study will provide recurrence-free and overall survival rates of groups in an unbiased fashion. Trial Registration EudraCT Number 2011-000218-20
Background: Multimorbidity is a phenomenon with high burden and high prevalence in the elderly. Our previous research has shown that multimorbidity can be divided into the multimorbidity patterns of 1) anxiety, depression, somatoform disorders (ADS) and pain, and 2) cardiovascular and metabolic disorders. However, it is not yet known, how these patterns are influenced by patient characteristics. The objective of this paper is to analyze the association of socio-demographic variables, and especially socio-economic status with multimorbidity in general and with each multimorbidity pattern.
Methods: The MultiCare Cohort Study is a multicentre, prospective, observational cohort study of 3.189 multimorbid patients aged 65+ randomly selected from 158 GP practices. Data were collected in GP interviews and comprehensive patient interviews. Missing values have been imputed by hot deck imputation based on Gower distance in morbidity and other variables. The association of patient characteristics with the number of chronic conditions is analysed by multilevel mixed-effects linear regression analyses.
Results: Multimorbidity in general is associated with age (+0.07 chronic conditions per year), gender (-0.27 conditions for female), education (-0.26 conditions for medium and -0.29 conditions for high level vs. low level) and income (-0.27 conditions per logarithmic unit). The pattern of cardiovascular and metabolic disorders shows comparable associations with a higher coefficient for gender (-1.29 conditions for female), while multimorbidity within the pattern of ADS and pain correlates with gender (+0.79 conditions for female), but not with age or socioeconomic status.
Conclusions: Our study confirms that the morbidity load of multimorbid patients is associated with age, gender and the socioeconomic status of the patients, but there were no effects of living arrangements and marital status. We could also show that the influence of patient characteristics is dependent on the multimorbidity pattern concerned, i.e. there seem to be at least two types of elderly multimorbid patients. First, there are patients with mainly cardiovascular and metabolic disorders, who are more often male, have an older age and a lower socio-economic status. Second, there are patients mainly with ADS and pain-related morbidity, who are more often female and equally distributed across age and socio-economic groups.
Because of the imbalance in the supply and demand of red blood cells (RBCs), especially for alloimmunized patients or patients with rare blood phenotypes, extensive research has been done to generate therapeutic quantities of mature RBCs from hematopoietic stem cells of various sources, such as bone marrow, peripheral blood, and cord blood. Since human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) can be maintained indefinitely in vitro, they represent potentially inexhaustible sources of donor-free RBCs. In contrast to other ex vivo stem-cell-derived cellular therapeutics, tumorigenesis is not a concern, as RBCs can be irradiated without marked adverse effects on in vivo function. Here, we provide a comprehensive review of the recent publications relevant to the generation and characterization of hESC- and iPSC-derived erythroid cells and discuss challenges to be met before the eventual realization of clinical usage of these cells.
Adipose tissue as a stem cell source is ubiquitously available and has several advantages compared to other sources. It is easily accessible in large quantities with minimal invasive harvesting procedure, and isolation of adipose-derived mesenchymal stromal/stem cells (ASCs) yields a high amount of stem cells, which is essential for stem-cell-based therapies and tissue engineering. Several studies have provided evidence that ASCs in situ reside in a perivascular niche, whereas the exact localization of ASCs in native adipose tissue is still under debate. ASCs are isolated by their capacity to adhere to plastic. Nevertheless, recent isolation and culture techniques lack standardization. Cultured cells are characterized by their expression of characteristic markers and their capacity to differentiate into cells from meso-, ecto-, and entodermal lineages. ASCs possess a high plasticity and differentiate into various cell types, including adipocytes, osteoblasts, chondrocytes, myocytes, hepatocytes, neural cells, and endothelial and epithelial cells. Nevertheless, recent studies suggest that ASCs are a heterogeneous mixture of cells containing subpopulations of stem and more committed progenitor cells. This paper summarizes and discusses the current knowledge of the tissue localization of ASCs in situ, their characterization and heterogeneity in vitro, and the lack of standardization in isolation and culture methods.
Eines der Hauptmerkmale, welches das Ionisch-Attische von den übrigen altgriechischen Dialekten unterscheidet, ist die Vertretung des idg. * ā durch ē. Idg. *ā kommt in den übrigen Dialekten als ā vor. So entspricht zum Beispiel dem idg. *māter (lat. māter, ai. mātā) äol.-dor. mā́tēr, aber mḗtēr im ion.-att. […] Selbstverständlich ist die Zurückführung auf idg. Formen mit ā ein Ergebnis, zu dem man erst durch die Rekonstruktionsmethoden der Vergleichenden Sprachwissenschaft kommt. In dem Bereich des ion.-att. Dialekts wird jedoch weiter unterschieden, da bei bestimmten lautlichen Umgebungen (nach den Lauten i, e und r) im Att. – wie auch im Äol., Dor. – ā und kein ē vorkommt, wie man erwarten würde und wie es wirklich der Fall im Ion. ist. […]
1.2. Wegen dieser unterschiedlichen phonologischen Situation, die man im Att. […] findet, stellen sich in Bezug auf das phonologische System des Altgriechischen (des ion.-att. Dialekts) die folgenden wesentlichen Fragen: (A) Wie soll man im Att. die Anwesenheit von ā statt des erwarteten ē erklären? (B) (I) Wurde das urgr. ā direkt zu ē (ē̡) im Ion.-att. oder hat es eine Zwischenstufe gegeben in dem Sinne, daß es zunächst zu ǟ (vorderer, palataler Laut) wurde und später zu ē̡, obwohl es in der Schrift immer durch H (MHTEP) im Att. repräsentiert wurde?
(II) Wenn es wirklich eine Zwischenstufe mit ǟ gegeben hat, hat sie so lange gedauert, daß ǟ als ein selbständiges Phonem des phonologischen Systems der langen Vokale des Ion.-att. und besonders des Att. betrachtet werden kann?
Der zweite Teil der Frage (B) wird direkt mit dem Problem der Chronologie der Verschmelzung ("merger") von ǟ und ā̡ verknüpft. (Da die Gründe, die für den phonematischen Wert des ǟ sprechen, stark genug sind, wie durch die folgende Analyse gezeigt werden wird, wird ǟ hier im voraus als Phonem betrachtet, und das soll hier auch als Arbeitshypothese dienen.)
Problemstellung: Die Junggrammatiker rekonstruierten die Paradigmen der idg. Verbalflexion nach dem Muster des formenreichen Altindischen und Altgriechischen; ihr Verfahren wird von weiten Kreisen noch heute befolgt. Seit dem Bekanntwerden des Hethitischen haben einzelne Forscher den umgekehrten Weg eingeschlagen und ein formenarmes System als Ausgangspunkt der Entwicklung erklärt.
The aim of any Automatic Translation project is to give a mechanical procedure for finding an equivalent expression in the target language to any sentence in the source language. The aim of my linguistic translation project is to find the corresponding structures of the languages dealt with. The two main problems that have to be solved by such a project are the difference of word order between the source language and the target language and the ambiguous words of the source language for which the appropriate word in the target language has to be chosen. The first problem is of major linguistic interest: once the project has been worked out, it will give us the parallel sentence structures for the two languages in question. Since there is no complete analysis of any language that could be used for the purpose of automatic translation, we decided to build up our project sentence by sentence. The rules which are needed for translating each sentence will have to be included in the complete program anyway, and the translation may be checked and corrected immediately. The program is split up into subroutines for each word-class, so that a correction of the program in case of an unsatisfactory translation does not complicate the program unnecessarily.
Georg von der Gabelentz (1840-1893) war Zeitgenosse und theoretischer Gegenspieler der Junggrammatiker. […] 1881 veröffentlichte er seine heute noch brauchbare 'Chinesische Grammatik', 1891 sein großes theoretisches Werk 'Die Sprachwissenschaft, ihre Aufgaben, Methoden und bisherigen Ergebnisse' (2. Auflage 1901 von A. Graf von der Schulenburg herausgegeben; Neudruck 1969 als 'Tübinger Beiträge zur Linguistik 1' von G. Narr und U. Petersen).
[...]
[I]m vorliegenden Zusammenhang [interessiert] die Frage, ob die Unterscheidung der beiden Systeme etwa für die genealogisch-historische Sprachforschung einen Fortschritt in der Theorie bedeutet. Die mannigfachen und oft widersprüchlichen Neigungen, Tendenzen usw. in der sprachlichen Entwicklung dürften teils im analytischen, teils im synthetischen System ihren letzten Grund haben. So scheint die konservative Tendenz in der Sprache auf dem analytischen System zu beruhen, während das synthetische System die Gelegenheit zur Fortentwicklung bietet und zu einer solchen durch die Vielfalt gebotener Ausdrucksmöglichkeiten anregt.
Within the last twenty years, the contraction method has turned out to be a fruitful approach to distributional convergence of sequences of random variables which obey additive recurrences. It was mainly invented for applications in the real-valued framework; however, in recent years, more complex state spaces such as Hilbert spaces have been under consideration. Based upon the family of Zolotarev metrics which were introduced in the late seventies, we develop the method in the context of Banach spaces and work it out in detail in the case of continuous resp. cadlag functions on the unit interval. We formulate sufficient conditions for both the sequence under consideration and its possible limit which satisfies a stochastic fixed-point equation, that allow to deduce functional limit theorems in applications. As a first application we present a new and considerably short proof of the classical invariance principle due to Donsker. It is based on a recursive decomposition. Moreover, we apply the method in the analysis of the complexity of partial match queries in two-dimensional search trees such as quadtrees and 2-d trees. These important data structures have been under heavy investigation since their invention in the seventies. Our results give answers to problems that have been left open in the pioneering work of Flajolet et al. in the eighties and nineties. We expect that the functional contraction method will significantly contribute to solutions for similar problems involving additive recursions in the following years.